Lv49
762 积分 2025-10-22 加入
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study
1小时前
待确认
Comparative Outcome Analysis of Lenvatinib Versus Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation
2小时前
待确认
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
2小时前
待确认
Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study
4天前
已完结
Letter to the Editor: Antibody-mediated rejection in liver transplantation following immune checkpoint inhibitors treatment
5天前
已完结
Extending the Use of Atezolizumab and Bevacizumab to a Liver Transplant Recipient: Need for a Posttransplant Registry
7天前
已完结
Artificial intelligence in liver cancer — new tools for research and patient management
7天前
已完结
Interventional therapy for hepatocellular carcinoma in the immunotherapy era: From mechanism exploration to materials innovation
7天前
已完结
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
9天前
已完结
Yttrium-90 radioembolization is associated with a lower risk of liver transplant waitlist dropout than chemoembolization in hepatocellular carcinoma
10天前
已完结
皖公网安备34019202002308
